Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients

Roussos, Louis; Florén, Claes‐Henrik; Carlson, Joyce; Svensson, Peter; Wallmark, Anders; Ekberg, Henrik

doi:10.1016/s0021-9150(99)80399-2

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APO-E polymorphism associating with renal insufficiency, in multiple studies, showed different data. Prevalence of E2 was reported among Japanese with renal insufficiency [41], E3/E4 among Sweden patients [42], and E3/4 and E4/4 in endstage renal disease secondary to IgA nephropathy [43]. Guz et al coincides with this study as no difference in E pattern was reported between hemodialysis and predialytic stage [44].…”

Section: Apolipoprotein E Resultssupporting

confidence: 78%

Apolipoprotein E and plasminogen activator inhibitor 1 gene polymorphism in children with chronic renal insufficiency associated with cardiovascular disease

Moustafa

Badr

Selim

et al. 2019

Egypt Pediatric Association Gaz

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) is considered a major cause of death in renal insufficiency (RI). Contributing genetic factors is a recent focus of research. This study aims to elucidate apolipoprotein E (APO-E) and plasminogen activator inhibitor 1 (PAI-1) gene polymorphisms in RI children associated with CVD. Methods: We studied 50 cases with chronic kidney disease (CKD) associated with CVD, and 30 healthy controls. Study sample was grouped as one on conservative treatment, the second on hemodialysis and the third was posttransplant. PAI-1 and APO-E gene polymorphisms were investigated using allele-specific polymerase chain reaction (AS-PCR) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) respectively. Results: 4G4G and 4G5G were the most common PAI-1 polymorphism denoting high association of 4 G allele in renal insufficiency associated with CVD with absent link to dyslipidemia, echocardiography changes or thrombosis. E3E3 was the most common among APO-E polymorphism without relation to dyslipidemia or thrombosis. Dyslipidemia was significantly linked to thrombosis. The study confirmed the role of dyslipidemia and hemodialysis in promoting thrombosis. Conclusion: Although PAI 4G Genotyping did not show significant association with echocardiography severity or thrombotic severity, yet genetic expression for high levels of PAI in plasma is expected in response to CRI factors known to trigger its release, in addition to those related to dialysis. APO-E3E3 genotyping showed a significant association with echocardiography severity as it enhances APO-A which contributes to CVD. The current study confirmed a significant association between dyslipidemia and CVD; however, the prevalent patterns 4G and E3E3 did not show a significant association with dyslipidemia. The genetic role for APO-A, B, O, or even other isomers for APO-E should be further studied as well.

show abstract

Section: Apolipoprotein E Resultssupporting

confidence: 78%

Apolipoprotein E and plasminogen activator inhibitor 1 gene polymorphism in children with chronic renal insufficiency associated with cardiovascular disease

Moustafa

Badr

Selim

et al. 2019

Egypt Pediatric Association Gaz

View full text Add to dashboard Cite

show abstract

“…Roussos et al. reported a higher prevalence (44% vs. 30%) of individuals carrying the E4 allele among a group of 112 Swedish renal transplant recipients (10). We did not find a higher frequency of the E4 allele when compared with the results obtained in our healthy population (7.7% vs. 9%) (9).…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein C-III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation

Rodrigo¹,

González‐Lamuño

Ruiz³

et al. 2002

American Journal of Transplantation

View full text Add to dashboard Cite

Hyperlipidemia and insulin resistance frequently develop after renal transplantation, contributing to cardiovascular disease. Individual differences in response based upon genetic variations in proteins regulating lipidic and glucose tolerance metabolism could be expected. In the general population, the S2 allelic variant of the apoprotein (apo) C-III gene has been associated with hypertriglyceridemia and an insulin resistant state, whereas the E4 allele of the apo E has been associated with hypercholesterolemia and atherosclerosis. Its influence in renal transplant patients remains to be seen. In order to assess the impact of apo E and C-III major polymorphisms on atherosclerotic vascular disease, lipid profile and impaired glucose tolerance in renal transplant patients, we studied 110 consecutively examined patients undergoing kidney transplantation (age range 24-73 years). Atherosclerotic complications were detected in 25% of patients, with age, male sex and hypercholesterolemia being significant atherosclerotic risk factors. Among the male patients with E4 allele, the odds ratio for coronary disease and global atherosclerosis were 10.2 (95% CI) and 6.4 (95% CI), respectively. There were no significant differences in the frequency of any of the polymorphisms among patients with dyslipidemia and impaired glucose tolerance. As the number of patients in our sample was small, larger studies are needed to verify these issues. While in the studied population C-III polymorphism appears to have little association with the prevalence of atherosclerotic complications, E4 allele should be considered as a genetic marker of coronary artery disease and global atherosclerosis in renal transplant patients.

show abstract

“…The impact of genetic susceptibility to development of dyslipidemia and atherosclerosis is presently under intense scrutiny, and in particular, interest has focused on variation at the apolipoprotein E (apo E) gene locus. So far only limited information on the impact of apo E locus on serum lipids, atherosclerotic complications and allograft functions in RTRs is available (4).…”

mentioning

confidence: 99%

Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function

Kahraman

Kıykım

Altun

et al. 2004

Clinical Transplantation

View full text Add to dashboard Cite

The pathogenetic events linking lipid metabolism and allograft functions and development of atherosclerosis are complex and multifactorial in RTRs. Our results showed that apo E genotypes have influences on lipids, lipoproteins and allograft functions. The ultimate role of apo E4 gene polymorphism as a risk factor for development and progression of atherosclerosis in RTRs should be sought in further studies.

show abstract

Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients

Cited by 3 publications

References 0 publications

Apolipoprotein E and plasminogen activator inhibitor 1 gene polymorphism in children with chronic renal insufficiency associated with cardiovascular disease

Apolipoprotein E and plasminogen activator inhibitor 1 gene polymorphism in children with chronic renal insufficiency associated with cardiovascular disease

Apolipoprotein C-III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation

Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function

Contact Info

Product

Resources

About